Delenex Therapeutics makes two senior appointments
Eric de La Fortelle joins as ceo and Jakob Schlapbach as cfo
La Fortelle was previously global head of external research and technologies at F. Hoffmann-La Roche and more recently global head, emerging technologies. His scientific work contributed to the field of protein structure determination and he was the initial lead author of the SHARP software, which contributed to the resolution of more than 1,000 protein structures by X-ray crystallography.
Schlapbach joined Delenex last December 2010 as cfo. He brings more than 30 years of banking and industrial financing experience to the company. He was cfo of Cytos Biotechnology for more than 10 years until mid-2010 and held the same position at Ascom group between 1994 and 2000.
Thomas Hecht, chairman of Delenex, said: ‘We are pleased and proud to have attracted two managers of such a high calibre to Delenex.’
Delenex Therapeutics AG is developing therapeutic PENTRA antibody fragments targeting serious medical diseases with high unmet need.
Delenex is a spin-off from ESBATech before its acquisition by Alcon in September 2009 and operates out of laboratories and offices in Zürich-Schlieren.
You may also like
Research & Development
Veraxa and Secarna Pharmaceuticals partner to advance AOC therapies for immune diseases
The pair will develop next-generation antibody oligonucleotide conjugates (AOCs) with the aim of unlocking novel targeted therapies for the treatment of autoimmune and chronic immune diseases